Evaluation of "Early Disease" in Familial Dilated Cardiomyopathy
Evaluation of the efficacy of carvedilol to reduce echocardiographically-determined left ventricular dimensions in asymptomatic individuals with suspected early disease in familial dilated cardiomyopathy.
St Vincent's Hospital, Darlinghurst
64 participants
Jul 10, 2003
Interventional
Conditions
Summary
The objective of this study is to determine whether active treatment with carvedilol will improve short-term echocardiographic in asymptomatic individuals with familial dilated cardiomyopathy.
Eligibility
Inclusion Criteria1
- Positive family history, absence of heart failure symptoms, increased left ventricular end-diastolic diameter (>112% predicted) with or without mild impairment of systolic function (ejection fraction 40-55%).
Exclusion Criteria1
- Chronic airflow limitation with >20% reversibility, heart rate less than 50 beats per minute, blood pressure <80/50mmHg.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
This study involves a randomised, double-blind, placebo-controlled trial to determine whether oral administration of carvedilol over a 6-month period will reduce left ventricular dimensions in asymptomatic individuals who have a family history of dilated cardiomyopathy and echocardiographic changes that are suspected to represent early disease.
Locations(1)
View Full Details on ANZCTR
For the most up-to-date information, visit the official listing.
ACTRN12605000204640